This study intends to prospectively enroll high-risk pregnant women to establish a multicenter cohort. By combining maternal basic characteristics, medical history, early pregnancy ultrasound, and biological markers, we aim to construct a joint predictive model for MVM-FGR.
Clinical guidelines do not recommend clinical screening for MVM-FGR in low-risk populations. Predictive models for FGR are often based on preeclampsia prediction models or Down syndrome serum screening models, which have limited utility. This study aims to establish a multi-center prospective cohort of pregnant women at high risk for FGR. We will collect baseline characteristics of pregnant women, ultrasound measurements of fetal growth, structural scans, maternal-fetal Doppler blood flow, as well as maternal serum and plasma in first and mid-trimester. Serum and plasma biomarker testing will be conducted. We will regularly observe fetal growth data, maternal-fetal complications during pregnancy, and collect delivery information, conditions of the newborn and placental pathology results after birth. By integrating maternal medical history, serum and plasma biomarkers, Doppler ultrasound, and other factors, we will establish a combined predictive model for early and mid-term MVM-FGR.
Study Type
OBSERVATIONAL
Enrollment
2,000
Shanghai First Maternity and Infant Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGPresent of maternal-vascular-malperfusion (MVM)-FGR
Development of MVM Fetal growth restriction
Time frame: during the pregnancy, up to an average gestational age of 40 weeks
Other adverse pregnancy outcome
including miscarriage, preeclampsia; intrauterine fetal death
Time frame: pregnancy-born after 28 days
GA at delivery, birth weight, neonatal outcomes.
GA at delivery, birth weight, neonatal outcomes.
Time frame: the day at birth
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.